MEDI4166(PCSK9抗体与GLP-1类似物融合分子)在超重或肥胖2型糖尿病患者中的随机1期剂量探索研究
本研究为在美国11家诊所开展的1期随机双盲研究,评估MEDI4166单次或多次给药在超重或肥胖2型糖尿病患者中的安全性和疗效。Part B中所有测试剂量(50 mg、200 mg、400 mg)均显著降低LDL-胆固醇水平(vs 安慰剂,均p<0.0001),但餐后血糖AUC0-4h无显著降低(均p>0.05)。MEDI4166耐受性可接受,药代动力学支持每周给药,治疗诱导的抗药抗体阳性率为22%。
要点
- MEDI4166在所有测试剂量下显著降低LDL-胆固醇水平,呈剂量依赖性。
- MEDI4166未显著降低餐后血糖AUC0-4h(vs 安慰剂,均p>0.05)。
- MEDI4166耐受性可接受,常见不良事件为注射部位反应、腹泻和头痛。
核心结论
- MEDI4166在超重或肥胖2型糖尿病患者中耐受性可接受,并显著降低LDL-胆固醇水平,但未显著降低餐后血糖。
研究设计与样本
- 本研究为在美国11家诊所开展的1期随机双盲研究,参与者按3:1随机接受MEDI4166或安慰剂。
- Part A设5个队列,单次皮下注射MEDI4166 10 mg、30 mg、100 mg、200 mg或400 mg或安慰剂。
- Part B设3个队列,每周一次皮下注射MEDI4166 50 mg、200 mg或400 mg或安慰剂,共5周。
- Part A主要终点为安全性;Part B共同主要终点为第36天LDL-胆固醇水平和混合餐耐量试验后血糖AUC0-4h较基线的变化。
- Part A中MEDI4166组n=30、安慰剂组n=10;Part B中MEDI4166组n=48、安慰剂组n=15。
主要发现
- 治疗中出现的不良事件发生率在Part A中MEDI4166组为60%、安慰剂组为50%;Part B中分别为79%和87%。
- MEDI4166常见不良事件包括注射部位反应、腹泻和头痛,无证据显示不良事件随剂量增加。
- Part B中所有测试剂量MEDI4166均显著降低LDL-胆固醇水平 vs 安慰剂(最小二乘均值[95%CI]:50 mg为-1.25[-1.66,-0.84];200 mg为-1.97[-2.26,-1.68];400 mg为-1.96[-2.23,-1.70];安慰剂为-0.03[-0.35,0.28];均p<0.0001)。
- Part B中MEDI4166 vs 安慰剂在混合餐耐量试验后血糖AUC0-4h无显著差异(最小二乘均值[95%CI]:50 mg为-10.86[-17.69,-4.02];200 mg为-4.23[-8.73,0.28];400 mg为-2.59[-7.14,1.95];安慰剂为-4.84[-9.95,0.28];均p>0.05)。
- MEDI4166的药代动力学特征支持每周给药,治疗诱导的抗药抗体阳性率为22%。
临床怎么用
- MEDI4166可能作为合并高LDL-胆固醇的超重或肥胖2型糖尿病患者的降脂候选药物,但需进一步研究验证。
- 该药物未显示餐后血糖获益,不能替代降糖治疗。
- 治疗期间需关注注射部位反应、腹泻和头痛等不良事件,并注意抗药抗体产生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes. MEDI4166 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody and glucagon-like peptide-1 (GLP-1) analogue fusion molecule designed to treat patients with type 2 diabetes who are at risk for cardiovascular disease. In this completed, first-in-human study, we evaluated the safety and efficacy of single or multiple doses of MEDI4166 in participants with type 2 diabetes. METHODS: In this phase 1 study that was conducted across 11 clinics in the USA, eligible adults had type 2 diabetes, a BMI of ≥25 kg/m2 to ≤42 kg/m2, and LDL-cholesterol levels ≥1.81 mmol/l. Participants were randomised 3:1 to receive MEDI4166 or placebo using an interactive voice/web response system, which blinded all participants, investigators and study site personnel to the study drug administered. In 'Part A' of the study, five cohorts of participants received a single s.c. injection of MEDI4166 at 10 mg, 30 mg, 100 mg, 200 mg or 400 mg, or placebo. 'Part B' of the study consisted of three cohorts of participants who received an s.c. dose of MEDI4166 once weekly for 5 weeks at 50 mg, 200 mg or 400 mg, or placebo. The primary endpoint in Part A was safety. The co-primary endpoints in Part B were change in LDL-cholesterol levels and area under the plasma glucose concentration-time curve (AUC0-4h) post-mixed-meal tolerance test (MMTT) from baseline to day 36. The pharmacokinetics and immunogenicity of MEDI4166 were also evaluated. RESULTS: MEDI4166 or placebo was administered to n = 30 or n = 10 participants, respectively, in Part A of the study, and n = 48 or n = 15 participants, respectively, in Part B. The incidence of treatment-emergent adverse events (TEAEs) were comparable between MEDI4166 and placebo in both Part A (60% vs 50%) and Part B (79% vs 87%) of the study. Common TEAEs with MEDI4166 included injection-site reactions, diarrhoea and headache; there was no evidence for dose-related increases in TEAEs. In Part B of the study, at all tested doses of MEDI4166, there was a significant decrease in LDL-cholesterol levels vs placebo (least squares mean [95% CI]; MEDI4166 50 mg, -1.25 [-1.66, -0.84]; MEDI4166 200 mg, -1.97 [-2.26, -1.68]; MEDI4166 400 mg, -1.96 [-2.23, -1.70]; placebo, -0.03 [-0.35, 0.28]; all p < 0.0001). However, there were no clinically relevant reductions or significant differences between MEDI4166 vs placebo in glucose AUC0-4h post-MMTT (least squares mean [95% CI]; MEDI4166 50 mg, -10.86 [-17.69, -4.02]; MEDI4166 200 mg, -4.23 [-8.73, 0.28]; MEDI4166 400 mg, -2.59 [-7.14, 1.95]; placebo, -4.84 [-9.95, 0.28]; all p > 0.05). MEDI4166 was associated with a pharmacokinetic profile supportive of weekly dosing and an overall treatment-induced anti-drug antibody-positive rate of 22%. CONCLUSIONS/INTERPRETATION: MEDI4166 was associated with an acceptable tolerability profile and significantly decreased LDL-cholesterol levels in a dose-dependent manner in overweight or obese patients with type 2 diabetes. However, there were no significant reductions in postprandial glucose levels at any dose of MEDI4166. TRIAL REGISTRATION: ClinicalTrials.gov NCT02524782 FUNDING: This study was funded by MedImmune LLC, Gaithersburg, MD, USA.
引用
- Jain M, Carlson G, Cook W, et al. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus. Diabetologia. 2018. PMID: 30593607. doi:10.1007/s00125-018-4789-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。